

Recommendations for the Use of Antibiotics in Primary and Secondary Esthetic Breast Surgery

Lukas Prantl, PhD*
 Arash Momeni, PhD†
 Vanessa Brebant, MD*
 Britta Kuehlmann, MD*†
 Norbert Heine, MD*
 Niklas Biermann, MD*
 Eva Brix, MD*

Summary: The use of systemic prophylactic antibiotics to reduce surgical-site infection in esthetic breast surgery remains controversial, although the majority of surgeons prefer to utilize antibiotics to prevent infection. Nonetheless, postoperative acute and subclinical infection and capsular fibrosis are among the most common complications following implant-based breast reconstruction. After esthetic breast augmentation, up to 2.9% of women develop infection, with an incidence rate of 1.7% for acute infections and 0.8% for late infections. After postmastectomy reconstruction (secondary reconstruction), the rates are even higher. The microorganisms seen in acute infections are Gram-positive, whereas subclinical late infections involving microorganisms are typically Gram-negative and from normal skin flora with low virulence. In primary implantation, a weight-based dosing of cefazolin is adequate, an extra duration of antibiotic cover does not provide further reduction in superficial or periprosthetic infections. Clindamycin and vancomycin are recommended alternative for patients with β -lactam allergies. The spectrum of microorganism found in late infections varies (Gram-positive and Gram-negative), and the antibiotic prophylaxis (fluoroquinolones) should be extended by vancomycin and according to the antibiogram when replacing implants and in secondary breast reconstruction, to target microorganisms associated with capsular contracture. All preoperative antibiotics should be administered <60 minutes before incision to guarantee high serum levels during surgical procedure. (*Plast Reconstr Surg Glob Open* 2020;8:e2590; doi: 10.1097/GOX.0000000000002590; Published online 24 January 2020.)

INTRODUCTION

Breast augmentation is one of the most popular procedures in plastic surgery worldwide. In 2017, 333,392 patients underwent breast augmentation, thus, making it the most commonly performed surgical procedure in the United States.¹ A particularly devastating postoperative complication is surgical-site infection (SSI), occurring in 2%–2.5% of patients following breast augmentation.² Importantly, one has to distinguish between early and late infection, the latter believed to be associated with the development of capsular contracture.^{3–7}

Acute infections occur between the first and the sixth week postoperatively. Clinical signs include erythema,

edema, and pain, in addition to changes in laboratory parameters, including leukocytosis and elevated c-reactive protein and procalcitonin. In contrast, late infections manifest months to years after implant placement and are often subclinical.⁸ In light of the devastating consequences of SSI, the issue of prophylactic antibiotic administration deserves special attention. The importance of this topic, however, is contrasted by the lack of widely accepted evidence-based guidelines addressing the issue of perioperative antibiotic prophylaxis. An unsolved problem remains prevention of capsular contracture. A variety of theories have been proposed related to its underlying pathomechanism, including immunologic factors and biofilm formation.^{4,9} Given these theories, prophylactic antibiotic administration, in addition to surgical technique (Bill Adams paper-14-point plan), appears to be a critical intervention.⁶ It is, therefore, not surprising that an increase in the use of antibiotics has been noted over time.¹⁰ Yet, it is important to acknowledge that antibiotics can have serious adverse drug events, including allergic reactions, bacterial resistance, and clostridium difficile infection.¹¹ Furthermore, it is unclear if antibiotics can effectively prevent biofilm formation following implant placement.¹²

From the *University Center of Plastic, Hand- and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany; and †Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University, Stanford, Calif.

Received for publication October 23, 2019; accepted October 28, 2019.

Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 \(CCBY-NC-ND\)](#), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/GOX.0000000000002590

Disclosure: The authors have no financial interest to declare in relation to the content of this article.

Several studies have demonstrated that bacterial contamination is present in up to 66% of patients with high-grade capsular contracture.¹³ In fact, studies of patients with breast implants have demonstrated that many implant pockets contain Gram-positive bacteria with the predominant species being local skin flora (coagulase-negative staphylococci [CNS], *Propionibacterium acnes*, *Corynebacterium* species). In light of this bacterial spectrum, the use of prophylactic ceftazolin seems justified.¹⁴ Recent studies hypothesize a discrepancy between antibiotic activity of commonly used antibiotics for preoperative prophylaxis of SSIs in patients with implant replacement and microorganisms found by sonication on breast implants, suspected to trigger the formation of capsular contracture.¹⁵

In several studies, an ultrasound bath of the explanted breast implants to create a fluid targeted with microorganisms was used (sonication).¹⁶ A significant correlation between degree of capsular contracture and culture positivity after sonication¹⁷ was targeted. The main group of bacteria found was *Propionibacterium* species and CNS^{18,19} (Fig. 1).

Prophylaxis

Preoperative antibiotics are used to prevent postoperative infections, including SSI²⁰ and bacteremia-induced joint prosthesis infection or infective endocarditis in high-risk patients.²¹

Breast augmentation is considered a clean procedure. However, breast tissue contains bacteria, thus, presenting a risk for implant contamination and postoperative infection.²² Preoperative risk factors for developing a SSI after breast surgery include advanced age, poor nutritional status, obesity, diabetes mellitus, smoking, presence of infection, immunodeficiency or immunosuppressive use, steroid use, recent surgery, long preoperative hospitalization, and colonization with microorganisms.^{4,23} In addition to patient factors, surgical technique can impact infection rates, as demonstrated by a higher number of SSIs

associated with periareolar or transareolar approaches.²⁴ Glove changes are recommended before treating the implants as well as the use of devices that minimize skin contact during implant insertion (“no touch technique”).^{17,25} Finally, the plane of implant insertion (subglandular versus subpectoral) and their surface characteristics (smooth versus textured) affect infection rates.^{26,27}

Ariyan et al presented the results of an evidence-based consensus conference on antibiotic prophylaxis for preventing SSI in plastic surgery.²⁸ They concluded that antibiotic prophylaxis (versus control) was associated with a significant risk reduction of SSI (2.5% versus 11.4%; odds ratio, 0.16; 95% CI, 0.04–0.61; *P*=0.01) for patients following breast augmentation.²⁸ These findings were, however, not replicated by Hardwicke et al who did not identify a beneficial effect of antibiotics on infection rates following breast augmentation.²⁹ Given these contradicting reports, a widely accepted consensus on antibiotic prophylaxis in augmentation mammoplasty is still lacking.³⁰ A reasonable approach might be to administer antimicrobial prophylaxis in clean wounds that are at risk of wound infection due to patient comorbidities or prolonged procedure length, complicated anatomy, choice of surgical technique/approach,³¹ and clean-contaminated wounds (implant-based breast cancer reconstruction).³² There is no evidence that prolonged postoperative antibiotic administration in primary or secondary cosmetic breast augmentation reduces postoperative complication rate, infection, or capsular contracture.^{33,34}

Choice of Antibiotics

Most surgeons prefer a first-generation cephalosporine for antibiotic prophylaxis.³⁵ The Sanford guide to antimicrobial therapy recommends ceftazolin 1–2 mg intravenous single shot preoperatively for breast surgery.³⁶ Early/acute infections occur within the first 6 weeks after surgery and are mainly caused by Gram-positive microorganisms of endogenous breast flora, such as *Staphylococcus aureus*, methicillin-resistant




Fig. 1. Differences between acute and late infections.




Fig. 2. Algorithm for the choice of antibiotics in esthetic breast surgery—augmentation. *Advanced age, negative nutritional status, obesity, diabetes mellitus, cigarette smoking, presence of infection, immunodeficiency or immunosuppressive use, steroid use, recent surgery, long preoperative hospitalization, and colonization with microorganism.

S. aureus, *Streptococcus pyogenes*, *P. acnes*, *Diphtheroids*, *Lactobacilli*, or *Bacillus* species.^{36,37} Clinical studies on capsular contracture as a common endpoint of late infection have identified a different bacterial spectrum, that is, *Propionibacterium avidum* and CNS.^{38,39} These species are not particularly susceptible to the commonly used cephalosporin. Hence, glycopeptides (vancomycin) have been proposed for the purpose of reducing the risk of capsular contracture because they are highly effective against Gram-positive organisms like *Propionibacterium* species and CNS.^{40,41} In concordance with this hypothesis, Chidester et al¹⁴ challenge the default use of cefazolin in a single-center study with 553 patients showing a relatively high resistance to cefazolin and clindamycin but vancomycin covering 100% of Gram-positive organisms.

For primary augmentation, cefazolin is most commonly recommended and is congruent with a recent report of 97% of plastic surgeons using this regimen.³⁵ In secondary implant breast reconstruction and when replacing implants, the use of fluoroquinolones and vancomycin is necessary due to extended microbiologic spectrum with Gram-positive and Gram-negative microorganism. When changing implants, it is recommended to obtain specimen for microbiologic examination. In addition to histologic examination of the capsule, seroma fluid (when present) should be examined for CD30 and anaplastic lymphoma kinase to exclude anaplastic large cell lymphoma (Fig. 2).^{42,43}

Duration and Timing of Antibiotic Prophylaxis

A single dose of intravenous antibiotic is adequate for prophylaxis in primary breast augmentation surgery and minimizes the risks associated with prolonged antibiotic use.⁴⁴ This is particularly important as prolonged antibiotic administration does not reduce postoperative infection rates.⁴⁵

The first dose of antimicrobial should be administered 60 minutes before skin incision. Vancomycin and fluoroquinolones should be administered within 120 minutes before skin incision due to the prolonged infusion

times required for these drugs. The longer half-lives of these antibiotics guarantee high serum levels during most surgical procedures.⁴⁶

In primary and secondary breast reconstruction, a perioperative single dose of intravenous antibiotic is enough. The timing should be 60 minutes before surgical incision for cephalosporins. If additional antibiotics are necessary (vancomycin/flourchinolone), administration should be done 120 minutes before incision.

CONCLUSIONS

In primary augmentation, a single dose of intravenous weight-based cefazolin before skin incision appears to be adequate. Clindamycin or vancomycin is recommended for patients with β -lactam allergies. In secondary breast surgery, that is, implant replacement, antibiotic coverage should be broadened to include flourchinolones and vancomycin.

Using the principles of the 14-point-plan by Adams et al⁶ to minimize the bacterial load at the time of surgery, the development of subclinical infection and capsular contracture may be reduced.

Eva Brix, MD

Department of Plastic and Reconstructive Surgery
University Hospital Regensburg
Franz-Josef-Strauss Allee 93053 Regensburg, Germany
eva.brix@ukr.de

REFERENCES

1. American Society of Plastic Surgeons. 2017 reconstructive plastic surgery statistics. *Reconstructive procedure trends*. American Society of Plastic Surgeons; 2018. <https://www.plasticsurgery.org/documents/News/Statistics/2017/reconstructive-procedure-trends-2017.pdf>. Accessed 13 January 2020.
2. Malavaud S, Reme C, Gangloff D, et al. Surgical site infection surveillance in breast implants surgery. *Ann Chir Plast Esthet*. 2005;50:134–137.
3. Dancey A, Nassimizadeh A, Levick P. Capsular contracture - what are the risk factors? A 14 year series of 1400 consecutive augmentations. *J Plast Reconstr Aesthet Surg*. 2012;65:213–218.

4. Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. *Plast Reconstr Surg*. 2009;124:1790–1796.
5. Tamboto H, Vickery K, Deva AK. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammoplasty. *Plast Reconstr Surg*. 2010;126:835–842.
6. Adams WP Jr, Calobrace MB. Discussion: the questionable role of antibiotic irrigation in breast augmentation. *Plast Reconstr Surg*. 2019;144:253–257.
7. Miller KE, Hontanilla B, Cabello A, et al. The effect of late infection and antibiotic treatment on capsular contracture in silicone breast implants: a rat model. *J Plast Reconstr Aesthet Surg*. 2016;69:70–76.
8. Basile AR, Basile F, Basile AV. Late infection following breast augmentation with textured silicone gel-filled implants. *Aesthet Surg J*. 2005;25:249–254.
9. Bachour Y, Bargon CA, de Blok CJM, et al. Risk factors for developing capsular contracture in women after breast implant surgery: a systematic review of the literature. *J Plast Reconstr Aesthet Surg*. 2018;71:e29–e48.
10. Lyle WG, Outlaw K, Krizek TJ, et al. Prophylactic antibiotics in plastic surgery: trends of use over 25 years of an evolving specialty. *Aesthet Surg J*. 2003;23:177–183.
11. Hensgens MP, Dekkers OM, Goorhuis A, et al. Predicting a complicated course of *Clostridium difficile* infection at the bedside. *Clin Microbiol Infect*. 2014;20:O301–O308.
12. Bergmann PA, Tamouridis G, Lohmeyer JA, et al. The effect of a bacterial contamination on the formation of capsular contracture with polyurethane breast implants in comparison with textured silicone implants: an animal study. *J Plast Reconstr Aesthet Surg*. 2014;67:1364–1370.
13. Virden CP, Dobke MK, Stein P, et al. Subclinical infection of the silicone breast implant surface as a possible cause of capsular contracture. *Aesthetic Plast Surg*. 1992;16:173–179.
14. Chidester JR, Danci I, Lewis P, et al. Antibidiogram for periprosthetic infections: a tool for better informed selection of empiric antibiotics for surgical site infections. *Ann Plast Surg*. 2016;76:S158–S161.
15. Reischies FMJ, Krause R, Holzer J, et al. What can we learn from sonication results of breast implants? *Plos One*. 2017;12:e0182267.
16. Rieger UM, Pierer G, Lüscher NJ, et al. Sonication of removed breast implants for improved detection of subclinical infection. *Aesthetic Plast Surg*. 2009;33:404–408.
17. Pajkos A, Deva AK, Vickery K, et al. Detection of subclinical infection in significant breast implant capsules. *Plast Reconstr Surg*. 2003;111:1605–1611.
18. Del Pozo JL, Tran NV, Petty PM, et al. Pilot study of association of bacteria on breast implants with capsular contracture. *J Clin Microbiol*. 2009;47:1333–1337.
19. Rieger UM, Djedovic G, Pattiss A, et al. Presence of biofilms on polyurethane-coated breast implants: preliminary results. *J Long Term Eff Med Implants*. 2016;26:237–243.
20. Porco TC, Gao D, Scott JC, et al. When does overuse of antibiotics become a tragedy of the commons? *Plos One*. 2012;7:e46505.
21. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev*. 2005;2:CD003543. doi:
22. Gylbert L, Asplund O, Berggren A, et al. Preoperative antibiotics and capsular contracture in augmentation mammoplasty. *Plast Reconstr Surg*. 1990;86:260–267; discussion 268.
23. Lewin R, Göransson M, Elander A, et al. Risk factors for complications after breast reduction surgery. *J Plast Surg Hand Surg*. 2014;48:10–14.
24. Wiener TC. Relationship of incision choice to capsular contracture. *Aesthetic Plast Surg*. 2008;32:303–306.
25. Dobke MK, Svahn JK, Vastine VL, et al. Characterization of microbial presence at the surface of silicone mammary implants. *Ann Plast Surg*. 1995;34:563–569; discussion 570.
26. Nannoum JD, Largent J, Kaplan HM, et al. Primary breast augmentation clinical trial outcomes stratified by surgical incision, anatomical placement and implant device type. *J Plast Reconstr Aesthet Surg*. 2013;66:1165–1172.
27. Olsen MA, Lefta M, Dietz JR, et al. Risk factors for surgical site infection after major breast operation. *J Am Coll Surg*. 2008;207:326–335.
28. Ariyan S, Martin J, Lal A, et al. Antibiotic prophylaxis for preventing surgical-site infection in plastic surgery: an evidence-based consensus conference statement from the American Association of Plastic Surgeons. *Plast Reconstr Surg*. 2015;135:1723–1739.
29. Hardwicke JT, Bechar J, Skillman JM. Are systemic antibiotics indicated in aesthetic breast surgery? A systematic review of the literature. *Plast Reconstr Surg*. 2013;131:1395–1403.
30. LeRoy J, Given KS. Wound infection in breast augmentation: the role of prophylactic perioperative antibiotics. *Aesthetic Plast Surg*. 1991;15:303–305.
31. Zhang Y, Dong J, Qiao Y, et al. Efficacy and safety profile of antibiotic prophylaxis usage in clean and clean-contaminated plastic and reconstructive surgery: a meta-analysis of randomized controlled trials. *Ann Plast Surg*. 2014;72:121–130.
32. Bağhaki S, Soybir GR, Soran A. Guideline for antimicrobial prophylaxis in breast surgery. *J Breast Health*. 2014;10:79–82.
33. Mirzabeigi MN, Sbitany H, Jandali S, et al. The role of postoperative antibiotics in reducing biofilm-related capsular contracture in augmentation mammoplasty. *Plast Reconstr Surg*. 2011;128:34e–35e. doi:
34. Townley WA, Baluch N, Bagher S, et al. A single pre-operative antibiotic dose is as effective as continued antibiotic prophylaxis in implant-based breast reconstruction: a matched cohort study. *J Plast Reconstr Aesthet Surg*. 2015;68:673–678.
35. Chopra K, Gowda AU, McNichols CHL, et al. Antimicrobial prophylaxis practice patterns in breast augmentation: a national survey of current practice. *Ann Plast Surg*. 2017;78:629–632.
36. Schreml S, Heine N, Eisenmann-Klein M, et al. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammoplasty. *Ann Plast Surg*. 2007;59:126–130.
37. Wixtrom RN, Stutman RL, Burke RM, et al. Risk of breast implant bacterial contamination from endogenous breast flora, prevention with nipple shields, and implications for biofilm formation. *Aesthet Surg J*. 2012;32:956–963.
38. Grice EA, Segre JA. The skin microbiome. *Nat Rev Microbiol*. 2011;9:244–253.
39. Rieger UM, Mesina J, Kalbermatten DF, et al. Bacterial biofilms and capsular contracture in patients with breast implants. *Br J Surg*. 2013;100:768–774.
40. Lohmeyer JA, Alawadi M, Bergmann PA, et al. [Adequate antibiotic prophylaxis and therapy of periprosthetic infections of the breast - review of 468 consecutive implant removals]. *Handchir Mikrochir Plast Chir*. 2017;49:91–102.
41. Cohen JB, Carroll C, Tenenbaum MM, et al. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. *Plast Reconstr Surg*. 2015;136:921–929.
42. Adams WP Jr, Culbertson EJ, Deva AK, et al. Macrot textured breast implants with defined steps to minimize bacterial contamination around the device: experience in 42,000 implants. *Plast Reconstr Surg*. 2017;140:427–431.
43. Doren EL, Miranda RN, Selber JC, et al. U.S. Epidemiology of breast implant-associated anaplastic large cell lymphoma. *Plast Reconstr Surg*. 2017;139:1042–1050.

44. Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. *Ann Surg Oncol*. 2009;16:2464–2469.
45. Khan UD. Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1,628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration. *Aesthetic Plast Surg*. 2010;34:42–47.
46. Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm*. 2013;70:195–283.